BIOMAT Database Logo BIOMAT Database Logo

Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2020

Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
College of Chemical Engineering, Nanjing Forestry University.

Inhibition of the epidermal growth factor receptor (EGFR) has been proved to be one of the most promising strategies for the treatment of non-small cell lung cancers. A series of 2-aryl-4-amino substituted quinazoline derivatives were designed and synthesized with the purpose to overcome L858R/T790M/C797S (CTL) triple mutant drug resistance and the biological activity for inhibition of CTL kinases and EGFR wild type (WT) were evaluated. Three compounds (20, 24 and 27) showed excellent inhibitory activities against EGFR kinases triple mutant CTL (IC50 < 1 µM) and high selectivity (IC50: WT/CTL >10000). Cell line evaluation showed that the most potent compound 27 was significantly potent against H1975-EGFR L858R/T790M (IC50 = 3.3 µM) and H1975-EGFR L858R/T790M/C797S (IC50 = 1.2 µM). Compound 27 also exhibited good microsomes stabilities in human, rat and mouse liver species, but low bioavailability. This work would be very useful for discovering new quinazoline derivatives as tyrosine kinase inhibitors targeting triple mutant L858R/T790M/C797S.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).
August 2019, Journal of medicinal chemistry,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
June 2016, Bioorganic & medicinal chemistry,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFRT790M/C797S inhibitors.
July 2023, Bioorganic & medicinal chemistry,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
January 2020, European journal of medicinal chemistry,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.
September 2015, ACS medicinal chemistry letters,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Design, synthesis, and biological evaluation of pyridoquinazoline derivatives as potent epidermal growth factor receptor inhibitors.
January 2013, Cancer biotherapy & radiopharmaceuticals,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
August 2020, Bioorganic & medicinal chemistry letters,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
January 2012, Anticancer research,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
February 1996, Journal of medicinal chemistry,
Mingguang Zhang, and Yunyun Wang, and Jia Wang, and Zhaogang Liu, and Jingmiao Shi, and Mingxin Li, and Yongqiang Zhu, and Shifa Wang
Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
December 2021, Bioorganic chemistry,
Copied contents to your clipboard!